-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $38

Benzinga·06/30/2026 13:58:42
Listen to the news
Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $35 to $38.